NASDAQ:PTI - Proteostasis Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.34 +0.02 (+1.52 %)
(As of 03/26/2019 12:30 PM ET)
Previous Close$1.31
Today's Range$1.31 - $1.47
52-Week Range$1.24 - $10.38
Volume6.02 million shs
Average Volume904,196 shs
Market Capitalization$68.14 million
P/E Ratio-0.57
Dividend YieldN/A
Beta-0.81
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study. The company is also involved in developing PTI-801, a corrector molecule; and PTI-808, a potentiator molecule that have been completed Phase I Study. It has a collaboration agreement with Astellas Pharma Inc. Astellas Pharma, Inc. to research and identify therapies targeting the UPR pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

Receive PTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTI
CUSIPN/A
Phone617-225-0096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.84 million
Book Value$2.25 per share

Profitability

Net Income$-61,830,000.00
Net Margins-2,170.32%

Miscellaneous

EmployeesN/A
Market Cap$68.14 million
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable

Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions

What is Proteostasis Therapeutics' stock symbol?

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics Inc (NASDAQ:PTI) posted its earnings results on Tuesday, November, 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.16. The firm earned $1.55 million during the quarter, compared to analysts' expectations of $1.38 million. Proteostasis Therapeutics had a negative net margin of 2,170.32% and a negative return on equity of 91.74%. View Proteostasis Therapeutics' Earnings History.

When is Proteostasis Therapeutics' next earnings date?

Proteostasis Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Proteostasis Therapeutics.

What price target have analysts set for PTI?

4 equities research analysts have issued 1 year target prices for Proteostasis Therapeutics' stock. Their forecasts range from $5.00 to $15.00. On average, they expect Proteostasis Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 782.4% from the stock's current price. View Analyst Price Targets for Proteostasis Therapeutics.

What is the consensus analysts' recommendation for Proteostasis Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteostasis Therapeutics.

What are Wall Street analysts saying about Proteostasis Therapeutics stock?

Here are some recent quotes from research analysts about Proteostasis Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and are lowering out 12-month PT to $14 from $21 on Proteostasis (due to lowering the probability of success on the program from 55% to 40%). This morning, the company announced and hosted a conference call to provide results from the low- and high-dose data from the triplet (PTI-801/808/428) trial. Additionally, the company announced data from the combination studies of on top of SYMDEKO. We feel the results were inferior to our projections, but believe data by year-end 2019 could make the case whether PTI’s internal drugs could be a competitive entrant in cystic fibrosis (CF)." (3/25/2019)
  • 2. According to Zacks Investment Research, "Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts. " (3/15/2019)

Has Proteostasis Therapeutics been receiving favorable news coverage?

News coverage about PTI stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Proteostasis Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.

Who are some of Proteostasis Therapeutics' key competitors?

What other stocks do shareholders of Proteostasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Rite Aid (RAD), Micron Technology (MU), BHP Group (BHP), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), vTv Therapeutics (VTVT), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Clearside Biomedical (CLSD) and Opko Health (OPK).

Who are Proteostasis Therapeutics' key executives?

Proteostasis Therapeutics' management team includes the folowing people:
  • Ms. Meenu Chhabra, Pres, CEO & Director (Age 47)
  • Dr. Benito Munoz, Chief Scientific Officer (Age 57)
  • Dr. Po-Shun Lee, Exec. VP & Chief Medical Officer (Age 50)
  • Ms. Sheila Gilbride Wilson, Chief Operating Officer
  • Ms. Janet L. Smart, VP of Intellectual Property & Legal Affairs (Age 62)

When did Proteostasis Therapeutics IPO?

(PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Who are Proteostasis Therapeutics' major shareholders?

Proteostasis Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Jennison Associates LLC (10.17%), Great Point Partners LLC (8.30%), BlackRock Inc. (7.96%), Sectoral Asset Management Inc (4.31%), venBio Select Advisor LLC (3.54%) and Hillhouse Capital Advisors Ltd. (2.36%). Company insiders that own Proteostasis Therapeutics stock include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Franklin M Berger, Meenu Chhabra and Po Shun Lee. View Institutional Ownership Trends for Proteostasis Therapeutics.

Which institutional investors are selling Proteostasis Therapeutics stock?

PTI stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Bailard Inc., Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. Company insiders that have sold Proteostasis Therapeutics company stock in the last year include Meenu Chhabra and Po Shun Lee. View Insider Buying and Selling for Proteostasis Therapeutics.

Which institutional investors are buying Proteostasis Therapeutics stock?

PTI stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Sectoral Asset Management Inc, venBio Select Advisor LLC, BlackRock Inc., Hillhouse Capital Advisors Ltd., Macquarie Group Ltd., Candriam Luxembourg S.C.A. and Bank of New York Mellon Corp. Company insiders that have bought Proteostasis Therapeutics stock in the last two years include Enterprise Associates 12 New, Franklin M Berger and Meenu Chhabra. View Insider Buying and Selling for Proteostasis Therapeutics.

How do I buy shares of Proteostasis Therapeutics?

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Proteostasis Therapeutics' stock price today?

One share of PTI stock can currently be purchased for approximately $1.36.

How big of a company is Proteostasis Therapeutics?

Proteostasis Therapeutics has a market capitalization of $69.41 million and generates $2.84 million in revenue each year. The company earns $-61,830,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

What is Proteostasis Therapeutics' official website?

The official website for Proteostasis Therapeutics is http://www.proteostasis.com.

How can I contact Proteostasis Therapeutics?

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]


MarketBeat Community Rating for Proteostasis Therapeutics (NASDAQ PTI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  221 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  457
MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote "Outperform" if you believe PTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Featured Article: Balance Sheet

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel